Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 revaccination study of RSVpreF in subsequent pregnancies
PACTR202601676008648Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Pfizer. Primary endpoints: Local reactogenicity in pregnant participants, Systemic reactogenicity in pregnant participants and 5 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on PACTR202601676008648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601676008648.